FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065730117> ?p ?o ?g. }

• W2065730117 endingPage "219" @default.
• W2065730117 startingPage "209" @default.
• W2065730117 abstract "Recent evidence suggest that the blockade of cannabinoid CB1 receptors might be beneficial to alleviate motor inhibition typical of Parkinson's disease (PD). In the present study, we have explored the motor effects of rimonabant, a selective antagonist of CB1 receptors, in a rat model of PD generated by an intracerebroventricular injection of 6-hydroxydopamine. Compared with rats subjected to unilateral injection of this toxin in the medial forebrain bundle, this model allows nigral dopaminergic neurons be symmetrically affected. Dose-response studies with 6-hydroxydopamine revealed that the application of 200 microg per animal caused hypokinetic signs (decreased ambulatory activity, increased inactivity, and reduced motor coordination), which paralleled several signs of degeneration of nigrostriatal dopaminergic neurons (dopamine depletion in the caudate-putamen, and decreased mRNA levels for tyrosine hydroxylase and superoxide dismutase-1 and -2 in the substantia nigra). In these conditions, the degree of hypokinesia and dopaminergic degeneration may be considered moderate, comparable to the disturbances occurring in early and middle stages of PD in humans, a period that might be appropriate to test the effects of rimonabant. There is also degeneration of other dopaminergic pathways out of the basal ganglia, but this does not appear to interfere significantly with the hypokinetic profile of these rats. Higher doses of 6-hydroxydopamine elevated significantly animal mortality and lower doses failed in general to reproduce motor inhibition. Like other animal models of PD, these rats exhibited an increase in the density of CB(1) receptors in the substantia nigra, which is indicative of the expected overactivity of the cannabinoid transmission in this disease and supports the potential of CB1 receptor blockade to attenuate hypokinesia associated with nigral cell death. Thus, the injection of 0.1 mg/kg of rimonabant partially attenuated the hypokinesia shown by these animals with no effects in control rats, whereas higher doses (0.5-1.0 mg/kg) were not effective. We also found that the antihypokinetic effects of low doses of rimonabant did not influence the dopamine deficits of these animals, as well as it did not modify GABA or glutamate transmission in the caudate-putamen. In summary, rimonabant may have potential antihypokinetic activity in moderate parkinsonism at low doses, but this effect is not related to changes in dopaminergic, GABAergic, or glutamatergic transmission in the striatum. Therefore, the elucidation of the neurochemical substrate involved in this effect remains a major challenge for the future." @default.
• W2065730117 created "2016-06-24" @default.
• W2065730117 creator A5000079852 @default.
• W2065730117 creator A5017106298 @default.
• W2065730117 creator A5048092704 @default.
• W2065730117 creator A5054775332 @default.
• W2065730117 creator A5068058486 @default.
• W2065730117 creator A5069868485 @default.
• W2065730117 date "2006-02-01" @default.
• W2065730117 modified "2023-10-01" @default.
• W2065730117 title "Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease" @default.
• W2065730117 cites W1513230591 @default.
• W2065730117 cites W1568165441 @default.
• W2065730117 cites W1775749144 @default.
• W2065730117 cites W1971766335 @default.
• W2065730117 cites W1974898145 @default.
• W2065730117 cites W1978211805 @default.
• W2065730117 cites W1985378942 @default.
• W2065730117 cites W1992854762 @default.
• W2065730117 cites W1998937162 @default.
• W2065730117 cites W2002062235 @default.
• W2065730117 cites W2011852660 @default.
• W2065730117 cites W2015614945 @default.
• W2065730117 cites W2020978550 @default.
• W2065730117 cites W2021950684 @default.
• W2065730117 cites W2025312022 @default.
• W2065730117 cites W2026057868 @default.
• W2065730117 cites W2027858732 @default.
• W2065730117 cites W2028904201 @default.
• W2065730117 cites W2033345218 @default.
• W2065730117 cites W2038487696 @default.
• W2065730117 cites W2040051923 @default.
• W2065730117 cites W2041366408 @default.
• W2065730117 cites W2042196312 @default.
• W2065730117 cites W2050453710 @default.
• W2065730117 cites W2052988246 @default.
• W2065730117 cites W2056413400 @default.
• W2065730117 cites W2060694966 @default.
• W2065730117 cites W2061909284 @default.
• W2065730117 cites W2073116630 @default.
• W2065730117 cites W2077648124 @default.
• W2065730117 cites W2090873558 @default.
• W2065730117 cites W2091396434 @default.
• W2065730117 cites W2099570835 @default.
• W2065730117 cites W2125004892 @default.
• W2065730117 cites W2161325655 @default.
• W2065730117 cites W2168882723 @default.
• W2065730117 cites W2172069328 @default.
• W2065730117 cites W4239398105 @default.
• W2065730117 cites W4247729308 @default.
• W2065730117 cites W4376848266 @default.
• W2065730117 doi "https://doi.org/10.1016/j.brainres.2005.12.014" @default.
• W2065730117 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16412990" @default.
• W2065730117 hasPublicationYear "2006" @default.
• W2065730117 type Work @default.
• W2065730117 sameAs 2065730117 @default.
• W2065730117 citedByCount "101" @default.
• W2065730117 countsByYear W20657301172012 @default.
• W2065730117 countsByYear W20657301172013 @default.
• W2065730117 countsByYear W20657301172014 @default.
• W2065730117 countsByYear W20657301172015 @default.
• W2065730117 countsByYear W20657301172016 @default.
• W2065730117 countsByYear W20657301172017 @default.
• W2065730117 countsByYear W20657301172018 @default.
• W2065730117 countsByYear W20657301172019 @default.
• W2065730117 countsByYear W20657301172020 @default.
• W2065730117 countsByYear W20657301172021 @default.
• W2065730117 countsByYear W20657301172022 @default.
• W2065730117 countsByYear W20657301172023 @default.
• W2065730117 crossrefType "journal-article" @default.
• W2065730117 hasAuthorship W2065730117A5000079852 @default.
• W2065730117 hasAuthorship W2065730117A5017106298 @default.
• W2065730117 hasAuthorship W2065730117A5048092704 @default.
• W2065730117 hasAuthorship W2065730117A5054775332 @default.
• W2065730117 hasAuthorship W2065730117A5068058486 @default.
• W2065730117 hasAuthorship W2065730117A5069868485 @default.
• W2065730117 hasConcept C126322002 @default.
• W2065730117 hasConcept C134018914 @default.
• W2065730117 hasConcept C137183658 @default.
• W2065730117 hasConcept C148001335 @default.
• W2065730117 hasConcept C159167319 @default.
• W2065730117 hasConcept C169760540 @default.
• W2065730117 hasConcept C170493617 @default.
• W2065730117 hasConcept C2776355744 @default.
• W2065730117 hasConcept C2776433454 @default.
• W2065730117 hasConcept C2776669363 @default.
• W2065730117 hasConcept C2776885963 @default.
• W2065730117 hasConcept C2779134260 @default.
• W2065730117 hasConcept C2779734285 @default.
• W2065730117 hasConcept C2780871563 @default.
• W2065730117 hasConcept C2780938664 @default.
• W2065730117 hasConcept C513476851 @default.
• W2065730117 hasConcept C71924100 @default.
• W2065730117 hasConcept C86803240 @default.
• W2065730117 hasConceptScore W2065730117C126322002 @default.
• W2065730117 hasConceptScore W2065730117C134018914 @default.
• W2065730117 hasConceptScore W2065730117C137183658 @default.
• W2065730117 hasConceptScore W2065730117C148001335 @default.

• next